A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

NCT ID: NCT04603833

Last Updated: 2021-02-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-02
• Study Completion Date: 2022-12-31

Brief Summary

The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific antigen (PSA) progression is superior to SHR3680 or Docetaxel single drug.

Conditions

Prostate Cancer Metastatic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SHR3680+Docetaxel

Group Type: EXPERIMENTAL

SHR3680+Docetaxel

Intervention Type: DRUG

Participants will receive SHR3680 combined with Docetaxel

SHR3680

Group Type: ACTIVE_COMPARATOR

SHR3680

Intervention Type: DRUG

Participants will receive SHR3680

Docetaxel

Group Type: ACTIVE_COMPARATOR

Docetaxel

Intervention Type: DRUG

Participants will receive Docetaxel

Interventions

SHR3680+Docetaxel

Participants will receive SHR3680 combined with Docetaxel

Intervention Type: DRUG

SHR3680

Participants will receive SHR3680

Intervention Type: DRUG

Docetaxel

Participants will receive Docetaxel

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically or cytologically confirmed prostate cancer; Unconfirmed neuroendocrine carcinoma or small cell carcinoma;

2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1;

3. Radiographic evidence of metastasis（CT/MRI/ECT);

4. Sustained therapy of luteinizing hormone-releasing hormone analogue(LHRHA)or received bilateral orchiectomy; patients who did not receive bilateral orchiectomy are willing to receive sustained therapy of LHRHA;

5. Evidence of prostate cancer progression under the sustained therapy of LHRHA or bilateral orchiectomy;

6. Adequate hepatic, renal, heart, and hematological functions;

7. Patients have given voluntary written informed consent before performance of any study-related procedure not part of normal medical care,with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care；

8. Expected to survive for at least 3 months；

9. Patient has been treated with Abiraterone and treatment failed；Treatment failure is defined as the progression of disease during treatment；

Exclusion Criteria

1. Have received any anti-tumor therapy in the past 4 weeks,including radiotherapy, chemotherapy, operation, targeted therapy, immuntherapy, and endocrinotherapy;

2. As a subject to participate in other drug clinical trials, the last test drug was administered within 4 weeks from the first dose of the study drug;

3. Plan to receive any other anti-tumor treatment during this trial;

4. Subjects have contraindications to prednisone, such as active infections or other conditions;

5. Subjects present any chronic condition requiring treatment with corticosteroids at doses greater than prednisone 5 mg, BID;

6. The investigators judged severe bone damage caused by tumor bone metastasis, including severely controlled bone pain, pathological fractures and spinal cord compressions that occurred in the last 6 months or are expected to occur in the near future;

7. Uncontrolled high blood pressure (systolic blood pressure 160 mmHg or diastolic blood pressure 95 mmHg). If blood pressure can be effectively controlled by antihypertensive therapy, subjects with a history of hypertension are allowed to participate in the study;

8. Study of active heart disease within 6 months prior to the first dose, including: severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, left ventricular ejection fraction <50%, and room for medication Arrhythmia;

9. Imaging diagnosis of brain tumor lesions;

10. history of pituitary or adrenal dysfunction;

11. Study of other malignant tumors within 5 years prior to the first dose (in situ cancer with complete remission and excluding malignant tumors with slow progress);

12. Patients with active HBV or HCV infection (HBV virus copy number #104 copies/mL, HCV virus copy number #103 copies/mL), or active syphilis infection;

13. History of immunodeficiency (including HIV positive, other acquired, congenital immunodeficiency disease) or organ transplant history;

14. Habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease; abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months before the first dose;

15. Patients who are unwilling to take effective contraceptive measures during the entire study period and within 3 months after the last dose

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Chunlei Jin, Ph.D.

Role: CONTACT

jinchunlei@hrglobe.cn

86-021-23511999

Qiang Wei, Ph.D.

Role: CONTACT

028-85423237

Facility Contacts

Qiang Wei, Ph.D.

Role: primary

Other Identifiers

SHR3680-II-203

Identifier Type: -

Identifier Source: org_study_id